Dicaris (Levamisole) 150 mg Tablets

Dicaris 150 mg and the decision it presents

Dicaris contains 150 mg of levamisole in each oral tablet. Its established role is as an anthelmintic, or medicine for susceptible worm infections, but the exact regimen depends on the parasite, the patient, and the clinical context. A 150 mg oral dose is an established adult regimen for some susceptible helminth infections, yet that does not make one tablet the correct treatment for every infection or every person.

The most important distinction for a US customer is the medicine's regulatory history. No FDA-approved US registration for Dicaris levamisole 150 mg tablets has been established from the supplied product information. Levamisole hydrochloride was previously marketed in the United States as Ergamisol, but that human-use product was withdrawn from the US market. Its former availability does not establish approval of Dicaris.

That context should guide the purchase decision. Before choosing an order quantity, confirm why levamisole is being considered, whether the fixed 150 mg tablet suits the intended regimen, and whether a more routinely used US treatment is available for the identified infection. The quantity in a package is a practical ordering choice, not evidence that all of those tablets belong in one course.

What is Dicaris, and where does levamisole fit?

Dicaris is the brand name of the current product, while levamisole is its active ingredient. The concrete product is a 150 mg tablet taken by mouth. It is not a liquid, chewable product, topical treatment, injectable medicine, or modified-release tablet.

Levamisole affects the neuromuscular activity of susceptible worms, leading to paralysis and allowing them to be cleared from the intestinal tract. Its usefulness therefore depends on whether the organism involved is susceptible. "Antiparasitic" is a broad category: medicines in this group do not all treat the same worms, protozoa, mites, or other parasites.

Levamisole also has immune-modulating effects. Those effects have led to specialized or historical use in settings such as warts, lichen planus, and treatment alongside other medicines for leprosy. These uses should not be treated as interchangeable with its role against worms, and a general skin infection is not, by itself, a reason to select Dicaris. The diagnosis, regimen, expected benefit, and monitoring can be substantially different.

Readers comparing a broader range can review our Antiparasitics category. If the actual question concerns malaria rather than an intestinal worm infection, Chloroquine belongs to a different treatment context and follows different prescribing and dosing principles.

Who may discuss Dicaris with a healthcare professional?

Dicaris may enter a treatment discussion for an adult with a confirmed or strongly suspected susceptible worm infection when levamisole is considered clinically appropriate. The decision should be based on the organism being treated, the intended dose, relevant health history, and the availability of alternatives. Similar-looking antiparasitic tablets are not automatically substitutes for one another.

The fixed 150 mg strength requires particular care in several situations:

• Children: pediatric levamisole dosing is based on body weight. A fixed 150 mg adult tablet should not be used as an unrestricted child dose, and a different strength or formulation may be needed.
• Pregnancy: established product information advises against use during pregnancy because adequate human safety information is lacking.
• Breastfeeding: use is generally avoided because transfer into human milk and the potential risk to a nursing infant have not been adequately established.
• Known allergy: anyone with hypersensitivity to levamisole or another tablet ingredient should not take the product.
• Blood-disorder history: levamisole has been associated with severe blood abnormalities, including agranulocytosis. A personal history of low white blood cell counts or another significant blood disorder warrants direct clinical review.
• Driving and safety-sensitive work: dizziness, drowsiness, or lethargy can make driving or operating machinery unsafe.

Diabetes alone is not identified in available product information as requiring a levamisole-specific dose adjustment. It is still important to provide a healthcare professional with a complete health and medication history rather than judging suitability from one condition in isolation.

How levamisole works in practice

Levamisole stimulates susceptible worms' neuromuscular system in a way that produces sustained muscle contraction and paralysis. The worms can then lose their hold in the intestinal tract and be removed through normal bowel activity. The medicine does not treat every cause of abdominal symptoms, and it does not confirm which parasite is present.

This mechanism helps explain why a single adult dose is used in some established regimens. It does not establish a universal one-dose rule. Some infections require a different medicine, repeat treatment, household hygiene measures, testing, or follow-up. Specialized uses based on levamisole's immune effects follow different clinical reasoning and may use different schedules.

A person considering Dicaris should therefore separate three questions: whether the condition is correctly identified, whether levamisole is active against it, and whether the 150 mg tablet provides the appropriate dose. The mechanism is relevant only after those questions have been addressed.

Using an oral tablet safely

Follow the regimen provided by a qualified healthcare professional or the directions supplied with the medicine. Do not assume that the quantity in the package represents the number of tablets to take, and do not repeat a dose merely because symptoms remain. Persistent symptoms may reflect the wrong diagnosis, reinfection, treatment failure, or a condition that requires another approach.

1. Confirm the intended number of 150 mg tablets and the timing before taking the first dose.
2. Take the tablet by mouth with water, following any product-specific directions about food or timing.
3. Do not divide, crush, or alter the tablet unless a pharmacist or prescriber confirms that doing so is appropriate for the particular product.
4. Record when the dose was taken, especially if follow-up treatment or testing has been recommended.
5. Avoid driving or operating machinery if dizziness, drowsiness, or lethargy occurs.

Alcohol should be avoided during treatment because unpleasant reactions have been reported when levamisole and alcohol are used together. A pharmacist or prescriber can advise how long to avoid alcohol for the intended regimen.

Store the tablets at room temperature between 59°F and 86°F in a dry place, protected from light, and keep them out of reach of children. Do not use tablets that are damaged, discolored, improperly stored, or beyond the expiration date shown on their packaging.

Available ordering quantities

Dicaris is available from us only in the 150 mg tablet strength. The listed quantities are 16, 32, 48, 60, 76, and 92 tablets. Because the strength does not change, the practical catalog choice concerns quantity rather than dose strength.

Choose a quantity only after the intended regimen is clear. A larger package should not be interpreted as a recommendation for a longer course, repeat self-treatment, preventive use, or treatment of several people. Adults and children may need different doses, and people in the same household may not have the same condition or contraindications.

For a defined regimen, compare the required tablet count with the available quantities and avoid treating surplus tablets as a routine supply. If the smallest listed quantity exceeds the planned course, consider the storage period and expiration date before ordering. Our support team can explain the quantities shown in our catalog, but it cannot replace an individualized diagnosis or select a treatment regimen on the basis of symptoms alone.

What outcomes and timing are reasonable to discuss?

The expected result depends on the infection and the regimen. For a susceptible intestinal worm infection, the treatment goal is clearance of the parasite and resolution of related symptoms. The time required for symptoms to improve varies, and symptom relief alone does not always prove that an infection has cleared.

A healthcare professional may recommend follow-up based on the organism involved, ongoing exposure, persistent symptoms, or the risk of reinfection. Depending on the situation, that follow-up may involve clinical review or laboratory testing. A repeat dose should be taken only when it is part of the recommended regimen.

Immune-related uses, including specialist use for warts, lichen planus, or as an adjunct in leprosy care, cannot be evaluated on the same timeline as treatment for intestinal worms. They may involve longer, more structured care and monitoring. Dicaris should not be selected for a skin lesion or "skin infection" without a clear diagnosis, because bacterial, fungal, viral, inflammatory, and parasitic skin conditions require different treatments.

Seek further advice if symptoms worsen, new symptoms develop, or the expected improvement does not occur. Severe or rapidly progressing symptoms should not be managed by taking additional tablets without assessment.

Safety priorities before treatment

The most serious established concern is the association between levamisole and blood disorders, including agranulocytosis, a severe reduction in infection-fighting white blood cells. Although not every user develops this complication, the potential severity makes warning symptoms important.

• Seek prompt medical advice for fever, chills, a persistent sore throat, mouth ulcers, or other signs of infection.
• Obtain urgent help for unusual bruising, bleeding, marked weakness, or symptoms of a serious allergic reaction.
• Do not take another dose while waiting for advice if a serious adverse reaction is suspected.
• Report suspected serious adverse events in the United States through a healthcare professional or FDA MedWatch.

Other possible adverse effects include nausea, abdominal discomfort, headache, dizziness, tiredness, and changes in taste. The presence, severity, and duration of adverse effects vary. New neurologic symptoms, severe skin reactions, or persistent vomiting warrant medical assessment.

Pregnancy, breastfeeding, pediatric dosing, known hypersensitivity, and a history of blood abnormalities deserve particular attention before use. The absence of one listed risk factor does not prove that the medicine is suitable, because the diagnosis and the complete medication history still matter.

Medication interactions and practical precautions

Provide a pharmacist or prescriber with a complete list of prescription medicines, nonprescription products, vitamins, and supplements. Interaction checking should be specific to levamisole rather than based only on its broad antiparasitic category.

Particular attention is appropriate for medicines that can affect blood cell counts or bone marrow function because levamisole has its own association with serious blood abnormalities. Anticoagulant treatment and medicines with narrow therapeutic ranges also warrant professional review rather than an assumption that a short regimen cannot interact.

Avoid alcohol during treatment because a disulfiram-like unpleasant reaction has been reported. If dizziness, drowsiness, or lethargy occurs, wait until the effects have fully resolved before driving, operating machinery, or carrying out other safety-sensitive tasks.

Do not combine Dicaris with another medicine for worms simply to broaden coverage. Combination treatment is appropriate only when it is selected for a diagnosed infection and the medicines, doses, and timing have been checked. Using several antiparasitic medicines together can increase adverse effects without treating the actual cause.

How does Dicaris compare with other options?

The best comparison is based on the identified parasite, patient factors, and regimen rather than tablet appearance or package price. Dicaris is not universally better or worse than another antiparasitic medicine; it is a distinct levamisole product with a fixed 150 mg strength and an important US regulatory history.

Albendazole or mebendazole may be discussed when broader or more routinely used treatment for intestinal worms is appropriate. Pyrantel pamoate may be a practical option for pinworm when its labeled use fits. Ivermectin may be considered for susceptible parasites requiring weight-based treatment. None should be substituted solely because it is another tablet for parasites.

Combantrin and Ergamisol may also appear in broader brand comparisons, but brand names can refer to different active ingredients or market histories. Ergamisol is particularly relevant as the former US levamisole product; it should not be mistaken for proof that Dicaris is currently FDA-approved.

US access changes the comparison

No FDA-approved US registration for Dicaris levamisole 150 mg tablets has been established from the supplied product information. Levamisole hydrochloride was previously marketed for human use in the United States as Ergamisol, but that product was withdrawn from the market. Dicaris should therefore not be presented as equivalent to a currently FDA-approved US levamisole product.

This regulatory position is separate from our ordering policy. Our current policy does not require customers to submit a prescription when placing an order for Dicaris. That commercial process does not determine whether the medicine is clinically appropriate, establish FDA approval, or replace advice from a licensed healthcare professional.

For a US customer, the decision is not simply whether Dicaris can be ordered. It is whether levamisole is a justified choice for the diagnosed condition when its safety profile, fixed strength, and lack of established FDA approval for this product are weighed against other available treatments. Suspected adverse events can be reported through FDA MedWatch.

Ordering and receiving Dicaris

When ordering from our catalog, select the 150 mg tablet quantity that corresponds most closely to a clearly defined regimen: 16, 32, 48, 60, 76, or 92 tablets. Review the product name, strength, quantity, destination details, and the shipping information presented during the order process before submitting it.

We have supported customers since 2017. Our support team is available 24/7 by email, online chat, and phone, and pharmacist support is available when a medicine-related question needs professional attention. Support can clarify catalog information and ordering details, but an individualized diagnosis or treatment choice requires an appropriate healthcare professional.

On receipt, confirm that the package is labeled Dicaris, that each tablet is identified as 150 mg levamisole, and that the quantity matches the order. Check the expiration date and inspect the packaging for damage or evidence of unsuitable storage. If the identity, strength, quantity, or condition is not as expected, do not take the tablets until the issue has been resolved.

A balanced final decision

Dicaris is a specific oral product containing 150 mg of levamisole per tablet. It may be relevant when a susceptible worm infection has been identified and the fixed adult strength fits the intended regimen. Its established adult single-dose use in some infections should not be expanded into a universal dosing rule, especially for children or specialized immune-related uses.

Before ordering, confirm four points: the condition being treated is one for which levamisole is appropriate; the 150 mg strength matches the recommended dose; pregnancy, breastfeeding, allergy, blood-disorder, interaction, and driving concerns have been considered; and the US regulatory history has been weighed against other suitable options. Larger listed quantities are useful only when they correspond to a legitimate, defined need.

If those points support Dicaris, choose the closest appropriate quantity rather than ordering extra tablets for unsupervised future use. If the diagnosis is uncertain, the dose is unclear, or a routinely used US alternative treats the infection more directly, resolve that question with a healthcare professional before taking levamisole.